{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:44:19Z","timestamp":1792842259031,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1053\/j.ajkd.2006.01.015","type":"journal-article","created":{"date-parts":[[2006,4,25]],"date-time":"2006-04-25T11:50:08Z","timestamp":1145965808000},"page":"715-726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Meta-Analysis of Biochemical and Patient-Level Effects of Calcimimetic Therapy"],"prefix":"10.1053","volume":"47","author":[{"given":"Giovanni F.M.","family":"Strippoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grahame","family":"Elder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Messa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2006.01.015_bib1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2003.12.003","article-title":"Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy","volume":"43","author":"Martin","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2006.01.015_bib2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.semnephrol.2003.08.013","article-title":"Osteoporosis and chronic kidney disease","volume":"24","author":"Stehman-Breen","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib3","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1046\/j.1523-1755.63.s85.26.x","article-title":"Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population","volume":"85","author":"Marco","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2006.01.015_bib4","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib5","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO4, Ca \u00d7 PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib6","doi-asserted-by":"crossref","first-page":"i9","DOI":"10.1093\/ndt\/gfh1002","article-title":"The importance of bone health in end-stage renal disease","volume":"19","author":"Malluche","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2006.01.015_bib7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib8","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/01.ASN.0000113243.24155.2F","article-title":"Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality","volume":"15","author":"Stevens","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib9","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/ki.1993.350","article-title":"Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease","volume":"44","author":"Hutchison","year":"1993","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2006.01.015_bib10","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0272-6386(95)90599-5","article-title":"Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance hemodialysis","volume":"26","author":"Qi","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2006.01.015_bib11","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/0272-6386(95)90453-0","article-title":"Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity","volume":"26","author":"Wang","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2006.01.015_bib12","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1651-2227.2000.tb00361.x","article-title":"Bone biopsy results and serum bone turnover parameters in uremic children","volume":"89","author":"Ziolkowska","year":"2000","journal-title":"Acta Paediatr"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2006.01.015_bib13","first-page":"S1","article-title":"K\/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease","volume":"42","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2006.01.015_bib14","unstructured":"CARI Guidelines. Available at: http:\/\/www.kidney.org.au\/cari\/guidelines.php. Accessed July 1, 2005"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2006.01.015_bib15","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0272-6386(04)01103-5","article-title":"Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"44","author":"Young","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2006.01.015_bib16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00003495-200363060-00005","article-title":"Hyperphosphatemia in renal failure","volume":"63","author":"Albaaj","year":"2003","journal-title":"Drugs"},{"key":"10.1053\/j.ajkd.2006.01.015_bib17","first-page":"327","article-title":"[Surgical treatment of secondary hyperparathyroidism in chronic kidney failure. Results of total parathyroidectomy with parathyroid autotransplantation]","volume":"130","author":"Courant","year":"1993","journal-title":"J Chir"},{"key":"10.1053\/j.ajkd.2006.01.015_bib18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1523-1755.2000.00183.x","article-title":"A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism","volume":"58","author":"Goodman","year":"2000","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2006.01.015_bib19","first-page":"1080","article-title":"Calcimimetics\u2014New drugs with the potential to control hyperparathyroidism","volume":"83","author":"Ott","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2006.01.015_bib20","unstructured":"Amgen Inc: Sensipar (Cinacalcet) HCl Tablets. Available at: http:\/\/www.fda.gov\/cder\/foi\/label\/2004\/21688_Sensipar_lbl.pdf. Accessed July 1, 2005"},{"key":"10.1053\/j.ajkd.2006.01.015_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2006.01.015_bib22","first-page":"460A","article-title":"Cincalcet HCl is an effective treatment for secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) not yet receiving dialysis","volume":"14","author":"Coburn","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib23","first-page":"460A","article-title":"Cincalcet HCl is an effective primary therapy for the management of secondary hyperparathyroidism","volume":"14","author":"Goodman","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib24","first-page":"462A","article-title":"Control of bio-intact parathyroid hormone (PTH) levels with the calcimimetic cinacalcet HCl in hemodialysis patients with secondary hyperparathyroidism (HPT)","volume":"14","author":"Martin","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib25","first-page":"463A","article-title":"Cincalcet HCl controls secondary hyperparathyroidism (HPT) in dialysis patients regardless of disease severity","volume":"14","author":"Quarles","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib26","first-page":"275A","article-title":"Long-term treatment of secondary hyperparathyroidism (HPT) with cinacalcet HCl (Sensipar) in patients receiving dialysis","volume":"15","author":"Sterrett","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 4","key":"10.1053\/j.ajkd.2006.01.015_bib27","first-page":"S150A","article-title":"Sustained, long-term reductions in parathyroid hormone (iPTH) after 3 years of treatment with the calcimimetic cinacalcet HCl in patients with secondary hyperparathyroidism (SHPT)","volume":"18","author":"Cunningham","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2006.01.015_bib28","series-title":"The effect of cincalcinet HCl on parathyroidectomy, fracture, hospitalization, and mortality in dialysis subjects with secondary hyperparathyroidism (HPT)","first-page":"219","author":"Cunningham","year":"2004"},{"key":"10.1053\/j.ajkd.2006.01.015_bib29","series-title":"Cinacalcet reduces parathyroid hormone (PTH) and calcium-phosphorus product (Ca \u00d7 P) regardless of concurrent changes in vitamin D administration","first-page":"319","author":"Fournier","year":"2004"},{"key":"10.1053\/j.ajkd.2006.01.015_bib30","series-title":"Greater achievement of NKF\/DOQI bone metabolism and disease targets with oral cinacalcet HCl in an EU\/Australian phase 3 study in hemodialysis subjects","first-page":"319","author":"De Francisco","year":"2004"},{"key":"10.1053\/j.ajkd.2006.01.015_bib31","series-title":"Cinacalcet HCl effectively reduces intact parathyroid hormone (iPTH) and Ca \u00d7 P irrespective of the severity of secondary hyperparathyroidism (HPT)","first-page":"219","author":"Frazao","year":"2004"},{"key":"10.1053\/j.ajkd.2006.01.015_bib32","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2006.01.015_bib33","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib34","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.ajkd.2004.08.029","article-title":"Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily","volume":"44","author":"Harris","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2006.01.015_bib35","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","article-title":"The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism","volume":"63","author":"Lindberg","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2006.01.015_bib36","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib37","series-title":"Cinacalcet HCl reduces bone turnover and bone marrow fibrosis in hemodialysis patients with secondary hyperparathyroidism (HPT)","first-page":"218","author":"Malluche","year":"2004"},{"key":"10.1053\/j.ajkd.2006.01.015_bib38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","article-title":"The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease","volume":"14","author":"Quarles","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib39","first-page":"863A","article-title":"Preliminary results from TARGET","volume":"15","author":"Chertow","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib40","first-page":"280A","article-title":"The CONTROL Study","volume":"15","author":"Reed","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib41","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1046\/j.1523-1755.63.s85.22.x","article-title":"Calcimimetic agents","volume":"85","author":"Urena","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2006.01.015_bib42","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2006.01.015_bib43","unstructured":"ANZDATA: 27th Annual Report. Available at: http:\/\/www.anzdata.org.au\/anzdata\/AnzdataReport\/download.htm. Accessed August 8, 2005"},{"key":"10.1053\/j.ajkd.2006.01.015_bib44","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1046\/j.1523-1755.2003_t01-1-00783.x","article-title":"Calcimimetics in action","volume":"53","author":"Sherrard","year":"1998","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2006.01.015_bib45","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/jama.282.8.771","article-title":"Users\u2019 guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate endpoints","volume":"282","author":"Bucher","year":"1999","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2006.01.015_bib46","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jama.282.8.786","article-title":"Surrogate endpoints, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease","volume":"282","author":"Psaty","year":"1999","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2006.01.015_bib47","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jama.282.8.790","article-title":"Are surrogate markers adequate to assess cardiovascular disease drugs?","volume":"282","author":"Temple","year":"1999","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2006.01.015_bib48","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1681\/ASN.V86965","article-title":"Lower probability of patient survival with continuous peritoneal dialysis in the United States compared with Canada","volume":"8","author":"Churchill","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib49","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal, as compared with low, hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2006.01.015_bib50","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1097\/01.ASN.0000130566.69170.5E","article-title":"Development, prevention and potential reversal of left ventricular hypertrophy in chronic kidney disease","volume":"15","author":"McMahon","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib51","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1111\/j.1600-6143.2004.00583.x","article-title":"Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation","volume":"4","author":"Borrows","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2006.01.015_bib52","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0272-6386(96)90396-0","article-title":"Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia","volume":"28","author":"Avram","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2006.01.015_bib53","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO4, Ca \u00d7 PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib54","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing haemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2006.01.015_bib55","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2006.01.015_bib56","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.1986.4.10.1529","article-title":"Publication bias","volume":"4","author":"Simes","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2006.01.015_bib57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/bmj.316.7124.61","article-title":"Meta-analysis bias in location and selection of studies","volume":"316","author":"Egger","year":"1998","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2006.01.015_bib58","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/bmj.326.7384.334","article-title":"Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis","volume":"326","author":"Juni","year":"2003","journal-title":"BMJ"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638606001120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638606001120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:45:25Z","timestamp":1759455925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638606001120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0272638606001120"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2006.01.015","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-Analysis of Biochemical and Patient-Level Effects of Calcimimetic Therapy","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2006.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}